Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGC-1502
- Development stage
- Unknown
- Lead developer
- BioKey
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RGC-1502 is an oncology program from Rgene Corporation/ABVC BioPharma being developed for pancreatic cancer as part of a clinical plan branded under BLEX 404, an oral liquid investigational drug evaluated in combination with gemcitabine. Public materials identify RGC-1502 as the pancreatic cancer program while referring to the study drug as BLEX 404; detailed mechanism of action for BLEX 404/RGC-1502 has not been disclosed in the cited sources. A Phase II trial is described to assess safety, dose, and response rate of BLEX 404 oral liquid plus gemcitabine in pancreatic cancer patients, sponsored by Rgene Corporation, with ABVC’s subsidiary BioKey contracted to guide the program through Phase II under FDA IND requirements.
- Other names
- BLEX 404BLEX404BLEX-404
Beyond the preview
Go deeper on RGC-1502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGC-1502.